SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron
The wide spectrum of SARS-CoV-2 variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of the immune response to different spike protein versions. Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) and B.1.1.529 (Omicron) in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure. We also observe that exposure to multiple spike variants increases the breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies.
SUMMARY: This study characterizes neutralization of eight different SARS-CoV-2 variants, including Delta and Omicron, with respect to nine different prior exposures, including vaccination, booster, and infections with Delta, Epsilon, and others. Different exposures were found to confer substantially differing neutralization specificity.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 22. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laurie, Matthew T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 13.03.2023 published: Electronic UpdateIn: J Infect Dis. 2022 Jan 03;:. - PMID 34979030 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.09.08.21263095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335165281 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335165281 | ||
| 003 | DE-627 | ||
| 005 | 20231225225235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.09.08.21263095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335165281 | ||
| 035 | |a (NLM)34981075 | ||
| 035 | |a (PII)2021.09.08.21263095 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laurie, Matthew T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: J Infect Dis. 2022 Jan 03;:. - PMID 34979030 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The wide spectrum of SARS-CoV-2 variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of the immune response to different spike protein versions. Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) and B.1.1.529 (Omicron) in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure. We also observe that exposure to multiple spike variants increases the breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies | ||
| 520 | |a SUMMARY: This study characterizes neutralization of eight different SARS-CoV-2 variants, including Delta and Omicron, with respect to nine different prior exposures, including vaccination, booster, and infections with Delta, Epsilon, and others. Different exposures were found to confer substantially differing neutralization specificity | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Liu, Jamin |e verfasserin |4 aut | |
| 700 | 1 | |a Sunshine, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, James |e verfasserin |4 aut | |
| 700 | 1 | |a Black, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Anthea M |e verfasserin |4 aut | |
| 700 | 1 | |a Mann, Sabrina A |e verfasserin |4 aut | |
| 700 | 1 | |a Pilarowski, Genay |e verfasserin |4 aut | |
| 700 | 1 | |a Zorn, Kelsey C |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Bravo, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Marquez, Carina |e verfasserin |4 aut | |
| 700 | 1 | |a Sabatino, Joseph J |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Mittl, Kristen |e verfasserin |4 aut | |
| 700 | 1 | |a Petersen, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Havlir, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a DeRisi, Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 22. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:22 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.09.08.21263095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 22 |c 12 | ||